newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

  • Cogent Biosciences submitted a New Drug Application to the FDA for bezuclastinib in NonAdvanced Systemic Mastocytosis on Dec. 30, 2025.
  • The submission relies on positive clinical data from the SUMMIT pivotal trial & Breakthrough Therapy Designation received in Oct. 2025.
  • The SUMMIT trial achieved statistical significance across all primary & key secondary endpoints, with improvements in 11 patient-reported symptoms & serum tryptase levels.
  • Updated 48-week data showed continued deepening of symptomatic improvement, indicating potential for sustained clinical benefit & chronic use.
  • Bezuclastinib demonstrated a favorable safety & tolerability profile suitable for patients with NonAdvanced Systemic Mastocytosis.
  • The company plans to submit two additional NDAs for bezuclastinib in Gastrointestinal Stromal Tumors & Advanced Systemic Mastocytosis in the first half of 2026.
  • These upcoming filings will be based on results from the PEAK & APEX clinical trials reported in Q4 2025.
  • Bezuclastinib is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation & other KIT exon 17 mutations.
  • Cogent Biosciences is also advancing an internally discovered FGFR2/3 inhibitor in Phase 1 & developing therapies targeting ErbB2, PI3Ka, KRAS, & JAK2 mutations.